Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-08-16
2011-08-16
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S354000, C546S183000, C546S282100, C546S340000, C548S246000
Reexamination Certificate
active
07998973
ABSTRACT:
A method of treating a tumor in a human patient is disclosed. The method comprises co-administering to the patient: (a) a dose of 1.5 mg tivozanib per day; and (b) a dose of 25 mg temsirolimus per week. In some embodiments of the invention, the tivozanib is administered on a repeating schedule of one dose per day for three weeks, followed by one week without tivozanib administration. The disclosed method is particularly suitable for treatment of renal cell carcinoma.
REFERENCES:
patent: 6821987 (2004-11-01), Kubo et al.
patent: 2006/0052415 (2006-03-01), Matsunaga et al.
patent: 2006/0094674 (2006-05-01), Neel et al.
patent: 2007/0105887 (2007-05-01), Moore
Atkins et al. 2004, Randomized Phase II Study of Multiple dose levels of CCI-779, a novel mTOR kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology, vol. 22, No. 5, pp. 909-918.
Eskens et al. “An open label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth fractor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced . . . .” Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, vol. 24, No. 18S (Jun. 20 Supplement), 2006, p. 2034.
AVEO press release dated Apr. 14, 2008 “AVEO Pharmaceuticals' novel triple VEGF Receptor inhibitor shows tumor regression in Patients with advanced renal cancer”.
Campas et al. Oct. 2009, “Tivozanib (AV-951, KRN-951)” Drugs of the Future, 34(10), pp. 793-796.
Eskens et al. Nov. 2006, “Phase I and pharmacological study of KRN951, a potent VEGFR tyrosine kinase inhibitor given in a 4 week on, 2 week.” Eur J Cancer Suppl (18th EORTC-NCI-AACR Symp Mol Targets Cancer Ther), 4(12), abstract 38.
Robinson et al. Oct. 2008, “Combination treatment of VEGFR inhibitor AV-951 and rapamycin reveals distinct mechanisms of each agent's anti-tumor activity” Eur J Cancer Suppl (20th EORTC-NCI-AACR Symp Mol Targents Cancer Ther), 6(12), abstract 53.
AVEO Pharmaceuticals, Inc., Jan. 31, 2008 Press Release (2 pages).
AVEO Pharmaceuticals, Inc., May 29, 2009 Press Release (3 pages).
Bhargava et al., “Updated Activity and Safety Results of a Phase II Randomized Discontinuation Trial (RDT) of AV-951, a Potent and Selective VEGFR1, 2, and 3 Kinase Inhibitor, in Patients with Renal Cell Carcinoma (RCC),”American Society of Clinical Oncology, J Clin Oncol 27:15s, 2009 (suppl; abstr 5032) (4 pages).
Patel et al., “Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma,”Clinical Genitourinary Cancer, vol. 7, No. 1, pp. 24-27, 2009.
Patnaik et al., “A Phase I, Pharmacokinetic and Pharmacodynamic Study of Sorafenib (S), a Multi-Targeted Kinase Inhibitor in Combination with Temsirolimus (T), an mTOR Inhibitor in Patients with Advanced Solid Malignancies.”Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 25, No. 185 (Jun. 20 Supplement), 2007: 3512.
Sosman et al., “Combination Targeted Therapy in Advanced Renal Cell Carcinoma,”Cancer2009, 115 (10 Suppl): 2368-2375.
AVEO Pharmaceuticals, “A Phase Ib, Open-Label, Dose-Finding Study to Evaluate the Safety of AV-951 in Combination with Temsirolimus in Subjects with Metastatic Renal Cell Carcinoma,” ClinicalTrials.gov Archive [online] Feb. 23, 2009 [retrieved on Mar. 8, 2001]. Retrieved from the internet <URL: http://clinicaltrials.gov/archive/NCT00563147/2009—02—23]; pp. 1-4.
AVEO Pharmaceuticals, “A Phase 2, Placebo-Controlled, Randomized, Discontinuation Trial of AV-951 in Patients with Renal Cell Carcinoma,” ClinicalTrials.gov Archive [online] Apr. 9, 2008 [retrieved on Mar. 9, 2001]. Retrieved from the internet <URL: http://clinicaltrials.gov/archive/NCT00502307/2008—04—09]; pp. 1-3.
Sanders, “New Drug Bulletin: Temsirolimus (Torisel-Wyeth),” University of Utah Hospitals & Clinics [online], Sep. 14, 2007 [retrieved on Mar. 8, 2011]. Retrieved from the internet <URL: healthcare.utah.edu/pharmacy/bulletins/NDB—139.pdf; pp. 1-2.
Fishman et al., “Abstract B60: Combination of tivozanib (AV-951) and temsirolimus in pateitns with renal cell carcinoma (RCC): Preliminary results from a phase 1 trial,” (Dec. 2009), Molecular Cancer Therapeutics: vol. 8, Issue 12, Supplement 1, Abstract B60.
International Search Report and Written Opinion dated Apr. 1, 2011.
Bhargava Pankaj
Esteves W. Brooke
Ryan John L.
AVEO Pharmaceuticals, Inc.
Goodwin & Procter LLP
McMillian Kara R
Padmanabhan Sreeni
LandOfFree
Tivozanib and temsirolimus in combination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tivozanib and temsirolimus in combination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tivozanib and temsirolimus in combination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635479